Sponsors (20)
The bill aims to make medical supply chains more resilient and faster by favoring 'trusted' partners, regulatory cooperation, and clearer review processes — improving access in crises and supporting some domestic industry — but does so at the cost of higher procurement and fiscal costs, greater trade‑policy complexity and risk of retaliation, potential weakening or politicization of health safeguards, and new administrative burdens.
Hospitals, clinics, and patients (including those with chronic conditions) would have more reliable access to medical devices, medicines, and supplies during emergencies because supply chains are diversified and mechanisms exist to prioritize critical imports and restore access.
Regulatory cooperation, expedited cross‑border movement, and streamlined authorization/licensing would speed delivery of medical products and support faster R&D collaboration and innovation.
Reducing dependence on a small number of foreign suppliers and enabling faster trade remedies strengthens national security by lowering vulnerability to export restrictions or foreign-pressure disruptions.
Hospitals, patients, and consumers could face higher prices because prioritizing 'trusted' or nearer suppliers and stronger IP protections may raise procurement costs and limit access to cheaper alternatives.
New trade preferences, restrictions, and enforcement actions risk provoking retaliation or other trade disruptions that could raise costs and harm U.S. businesses and consumers.
Efforts to expedite approvals and harmonize regulations — combined with politically driven congressional review or blocking of agreements — could weaken regulatory safeguards or politicize access to lower‑cost emergency measures, increasing health‑safety risks.
Based on analysis of 7 sections of legislative text.
Authorizes the President to negotiate "trusted trade partner" agreements to lower trade barriers and harmonize rules for medical goods, subject to congressional review and monitoring.
Official title: To authorize the President to enter into trade agreements for the reciprocal elimination of duties or other import restrictions with respect to medical goods to contribute to the national security and public health of the United States, and for other purposes.
Introduced March 18, 2025 by Nicole Malliotakis · Last progress March 18, 2025
Authorizes the President and the U.S. Trade Representative to negotiate "trusted trade partner" agreements with foreign countries to remove or modify duties and other trade barriers for medical goods, and to promote regulatory cooperation, supply diversification, procurement access, IP protections, and R&D collaboration to strengthen U.S. medical supply chain resilience. Agreements may be proclaimed only after advance notice, consultation with agencies and advisory bodies, repeated reporting to Congress, and a multi-step congressional review and potential disapproval process; the USTR must monitor partner compliance and the President must act on any findings of noncompliance.